New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma

In conclusion, our results suggest new promising combination regimes for treatment of UC, also in the cisplatin-resistant setting.PMID:38693852 | DOI:10.1111/jcmm.18342

Source: Molecular Medicine - May 2, 2024 Category: Molecular Biology Authors: Sarah Meneceur Caroline E De Vos Patrick Petzsch Karl K öhrer G ünter Niegisch Mich èle J Hoffmann Source Type: research